
The Bio Report
Levine Media Group
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Episodes (1239)
Enlisting the Immune System in the War on Cancer
The Bio Report
Why Scientists Must Also Be Advocates
The Bio Report
Sernova Eyes Range of Disease for Implantable Cell Technology
The Bio Report
Stratus Wants to Demonstrate Its Telehealth Fluency
The Bio Report
Regeneron Embraces Genetics as Fundamental to Drug Development
The Bio Report
Despite FDA Setback, KemPharm Advancing Prodrug Pipeline
The Bio Report
Using digital technologies to improve diagnosis and treatment of mental health p...
The Bio Report
Biotech in 2016 and the Year Ahead with TheStreet’s Adam Feuerstein
The Bio Report
Harnessing Gut Bacteria to Treat Disease
The Bio Report
A Look at What’s Ahead for Biopharma in 2017
The Bio Report
AMA Wants Docs to Have Seat at mHealth Table
The Bio Report
Testing of New HIV Vaccine Carries Hopes of a Breakthrough
The Bio Report
Centrexion Takes Aim at Pain with Growing Portfolio of Non-Opioid Therapeutics
The Bio Report
Bringing Women into Biotech Boardrooms
The Bio Report
Novartis Deal Validates Perlara’s Approach to Rare Disease Drug Discovery
The Bio Report
Harvesting the Aquatic Microbiome for New Drugs
The Bio Report
How TwoXAR Is Using Big Data to Accelerate Drug Discovery
The Bio Report
Developer of innovative catheter for cancer drugs turns to crowdfunding
The Bio Report
Harnessing Real World Samples and Data to Speed Biomedical Research
The Bio Report
A Rich Pipeline Expected to Drive Industry’s Growth
The Bio Report
Harnessing Biology to Transform the Economy
The Bio Report
How a Predictive Diagnostic Can Reduce Preterm Births
The Bio Report
Building Better Drugs for Psychiatric Disorders by Targeting the Causes
The Bio Report
The Role of PBMs in the Controversy over Drug Pricing
The Bio Report
Why a Rare Genetic Disease May Shed Light on Normal Aging
The Bio Report
Battling Zika and Other Diseases Like It
The Bio Report
Chronicling a Trailblazer of the Genomics Age
The Bio Report
Great Progress, but Concerns Persist About Cancer Care in America
The Bio Report
Improving Healthcare by Addressing the Most Challenging Patients
The Bio Report
The Case for Chasing Unpopular Indications
The Bio Report
Improving Drug Development through Better Use of Biomarkers
The Bio Report
Measuring the Value of Incubators and Accelerators
The Bio Report
Enlisting New and Old Tools to Combat Antibiotic Resistance
The Bio Report
Advancing Cancer Care with New Diagnostic Tools
The Bio Report
A Biotech Reinvents Itself and How to Price Drugs
The Bio Report
Using Technology to Modernize Preclinical Development
The Bio Report
Can the Biotech Industry Stay on Track through Innovative Pricing
The Bio Report
Wall Street Turns Its Eyes to ASCO
The Bio Report
Understanding the Disease It Never Was on House
The Bio Report
Why the State of Innovation Is Encouraging
The Bio Report
Can Market Forces Fix Drug Pricing
The Bio Report
Digital Health Device Seeks to Push Beyond Cannabis to Test Food, Air, and Water
The Bio Report
Why the Cancer Moonshot Offers a Chance to Rethink Funding Priorities
The Bio Report
Medtronic Advances Toward an Artificial Pancreas
The Bio Report
Using Real-Time Data to Detect HIV Outbreaks
The Bio Report
Why Pharma Needs to Forge New Drug Pricing Models
The Bio Report
Gensight Targets Gene Therapy on Diseases that Blind
The Bio Report
A Vial Problem: How We Waste $3 Billion of Cancer Drugs a Year
The Bio Report
The Havoc-Wreaking Zombies Lurking in Life Sciences Boardrooms
The Bio Report
New FDA Chief Faces Challenges
The Bio Report